Avantor, Inc. (NYSE:AVTR) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Avantor, Inc. (NYSE:AVTR) have been given an average rating of “Moderate Buy” by the fifteen research firms that are currently covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation and twelve have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $27.57.

Several equities research analysts have recently commented on AVTR shares. Robert W. Baird reduced their target price on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a research note on Monday, October 28th. Barclays cut their price target on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a report on Friday, October 25th. Wells Fargo & Company decreased their price objective on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating on the stock in a research note on Monday, October 28th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $34.00 price objective on shares of Avantor in a report on Thursday, September 26th. Finally, UBS Group reduced their target price on Avantor from $30.00 to $29.00 and set a “buy” rating on the stock in a report on Tuesday, October 8th.

Avantor Price Performance

Shares of AVTR stock opened at $21.06 on Friday. The stock’s fifty day simple moving average is $23.28 and its 200 day simple moving average is $23.72. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.54 and a quick ratio of 1.06. The firm has a market cap of $14.33 billion, a price-to-earnings ratio of 45.78, a P/E/G ratio of 2.55 and a beta of 1.35. Avantor has a one year low of $19.59 and a one year high of $28.00.

Insider Activity at Avantor

In related news, CAO Steven W. Eck sold 3,525 shares of the business’s stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $25.06, for a total transaction of $88,336.50. Following the completion of the sale, the chief accounting officer now directly owns 29,544 shares of the company’s stock, valued at $740,372.64. The trade was a 10.66 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 1.50% of the stock is owned by company insiders.

Institutional Trading of Avantor

Institutional investors have recently bought and sold shares of the business. Tidal Investments LLC lifted its stake in Avantor by 19.6% in the first quarter. Tidal Investments LLC now owns 14,654 shares of the company’s stock valued at $375,000 after buying an additional 2,399 shares during the period. Swedbank AB bought a new stake in shares of Avantor in the 1st quarter valued at about $2,707,000. Cetera Advisors LLC acquired a new stake in shares of Avantor in the 1st quarter valued at approximately $249,000. DekaBank Deutsche Girozentrale boosted its stake in Avantor by 146.7% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 400,736 shares of the company’s stock worth $10,205,000 after acquiring an additional 238,285 shares during the last quarter. Finally, DNB Asset Management AS grew its holdings in Avantor by 7.6% during the second quarter. DNB Asset Management AS now owns 118,739 shares of the company’s stock valued at $2,517,000 after purchasing an additional 8,436 shares during the period. Institutional investors and hedge funds own 95.08% of the company’s stock.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.